Equities
  • Price (USD)0.5898
  • Today's Change0.030 / 5.32%
  • Shares traded62.44k
  • 1 Year change-65.31%
  • Beta0.6197
Data delayed at least 15 minutes, as of Nov 15 2024 20:52 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

  • Revenue in USD (TTM)12.52m
  • Net income in USD-102.09m
  • Incorporated2002
  • Employees108.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SCYNEXIS Inc8.57m-36.44m45.54m29.00--0.7779--5.32-0.756-0.7560.1771.540.0692--3.61295,379.30-29.44-30.02-35.54-36.35-71.42---425.41-86.76----0.1843--2,652.72252.64206.74------
BGM Group Ltd29.87m-7.86m47.77m298.00--1.09--1.60-1.10-1.104.186.070.52373.7325.96100,236.40-14.432.71-17.013.862.9211.66-27.562.726.06-0.75270.0026.11-28.35-1.60-822.64--12.86--
Odonate Inc0.00-102.07m49.87m137.00--1,839.01-----13.59-13.590.009.270.00----0.00-66.98-58.36-83.00-65.14------------0.00-------12.99------
Aadi Bioscience Inc25.07m-61.69m52.01m53.00--0.7542--2.07-2.29-2.290.92852.800.22250.6964.09281,685.40-54.75-50.25-65.27-56.1587.39---246.06-473.974.54--0.00--60.063.85-8.68--153.54--
DBV Technologies SA - ADR12.52m-102.09m60.97m108.00--0.525--4.87-1.18-1.180.14871.120.0885--0.6757120,336.50-72.19---92.61-------815.73------0.00--224.69--24.46------
bluebird bio Inc53.12m-300.52m62.21m375.00------1.17-1.84-1.840.3039-0.02980.09852.034.42141,653.30-55.72-34.75-96.37-40.84-43.49-124.35-565.74-5,770.410.3272-13.371.03--720.04-11.588.00---30.47--
OptiNose Inc75.67m-31.15m65.59m132.00------0.8667-0.2216-0.22160.5416-0.27250.65120.76592.96573,272.80-26.80-48.25---98.9590.2186.96-41.16-131.660.7198-1.611.48---6.9358.6452.58---27.96--
Global Pharmatech Inc.3.18m-2.24m67.19m217.00--0.4959--21.13-0.0964-0.09640.13670.34280.22921.593.5714,649.77-16.44---22.55--46.21---71.75--1.62-9.870.2223--32.43---142.03------
CASI Pharmaceuticals Inc23.10m-27.21m71.43m176.00--7.92--3.09-2.03-2.031.720.67310.35770.89172.39131,250.00-41.56-34.75-62.38-46.9156.8155.98-116.17-153.722.36--0.6718---21.41--34.27--14.65--
Cellectar Biosciences Inc0.00-48.74m75.45m20.00--14.70-----2.51-2.510.000.38390.00----0.00-271.59-83.69-682.65-99.80-----------41.970.00-------32.80--17.55--
Rockwell Medical Inc98.92m-1.24m76.11m237.00------0.7694-0.0482-0.04823.25--------417,371.30---46.29---65.3816.914.66-1.25-36.51--0.3194----14.845.6954.82--76.21--
Journey Medical Corp77.68m843.00k76.83m58.0051.409.1518.730.9891-0.0131-0.01313.910.56421.152.365.711,339,328.001.25--5.17--66.79--1.09--1.082.000.6682--7.48--87.00------
Assertio Holdings Inc125.76m-68.49m77.36m53.00--0.5928--0.6151-0.7212-0.72121.321.370.38340.90522.342,372,887.00-20.88-21.51-30.33-32.0570.3188.68-54.46-62.101.57--0.2293---2.67-13.38-402.80---28.25--
Procaps Group SA414.10m52.20m77.85m5.50k1.321.981.120.1880.52090.52094.160.34910.8541.873.3875,290.1810.77--19.01--55.04--12.61--0.9861--0.8829--0.0434--142.18------
Data as of Nov 15 2024. Currency figures normalised to Dbv Technologies SA's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.